drugset / Trial / NCT05896137

CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)

NCT05896137

Phase 2 Active not recruiting 50 enrolled Cascade Pharmaceuticals, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

A phase II Study of CS0159 in Chinese patients with PSC(Primary Sclerosing Cholangitis)

Timeline

Start
2023-08-07
Primary completion
2025-11-14
Completion
2026-05

Drugs

EvaluationDrugModalityDoseRoute
Subject CS0159 Unknown 2 mg Oral
Subject CS0159 Unknown 4 mg Oral